Lead author Adam Gaffney is a pulmonologist and critical care physician at the Cambridge Health Alliance. Here's the summary, from the BMJ: Key messages The US and Canadian pharmaceutical systems are dysfunctional Costs are exorbitant, commercial goals distort drug development, misleading promotion fosters misuse, and medications are too often unaffordable for patients We propose reforms that … Continue reading Cambridge Mass. doc leads call for reform of “dysfunctional” pharmaceutical system.
Probably not, but you never know. Maybe someone will get lucky. Also know that today's (Thursday) cancer mini-golf tournament is rescheduled to Friday. Be a Medicine Hunter April 19 @ 1:00 pm - 4:00 pm Novartis, 22 Windsor St. Cambridge USA Novartis scientists are hunting for new medicines that will change the practice of medicine and improve patients’ lives. Meet … Continue reading Make your own #pharmaceuticals Thursday at the #CambSciFest
STAT News reports that Partners Healthcare CEO Dr. David Torchiana was among the health care executive who met with President-elect Donald Trump Wenesday. Torchiana has been among those arguing that repeal of the law could disrupt millions of families who have relied upon it for insurance coverage. “De-insuring 20 million people, many of whom were probably Trump … Continue reading From today’s Boston Globe: Partners and Trump, health costs and another expensive drug
In her "Gut Check" column, STAT's Sharon Begley notes that a NEJM report from Boston University's Framingham Heart Study claims that "The percent of people developing dementia each year is falling significantly... raising hope that some cases can be prevented and, possibly, that the worst forecasts of a “looming dementia crisis in the United States are overblown" … Continue reading #STATnews asks: Are #Alzheimer’s numbers inflated?
The New York Times reports: As complaints grow about exorbitant drug prices, pharmaceutical companies are coming under pressure to disclose the development costs and profits of those medicines and the rationale for charging what they do. So-called pharmaceutical cost transparency bills have been introduced in at least six state legislatures in the last year, aiming … Continue reading Massachusetts thread in NYTimes story on drug price rekoning
Robert Weisman of the Globe reports today: California scientist Paul M. Quinton learned that he has cystic fibrosis at age 19 and has spent his long career in his lab working on ways to cure it. He is, in short, not the kind of person you’d expect to be fighting with Vertex Pharmaceuticals Inc., the … Continue reading Why won’t the Cystic Fibrosis Foundation comment on the high price of the new Vertex drug?
The scene at the FDA hearing was familiar. All the advisory committees have seen it play out again and again. Yesterday, it was the Pulmonary-Allergy Drug committee: The pharma doc with the convincing statement. The weeping patients. The drug likely to cost a couple thousand a month offering a slim benefit over an existing drugs. … Continue reading Should the FDA approve Vertex’s new cystic fibrosis drug?